Signal category
Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.
Phase readouts, trial design shifts, endpoint changes, and safety signals that move the clinical risk-reward calculus.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.
The inVitD Trial aims to assess the effects of vitamin D supplementation on menstrual cycle hormones in women aged 19-40.
The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.
The study evaluates the implementation of the ACS GSV Program at James Cancer Hospital to enhance surgical outcomes for older adults.
The CANUT Junior study is assessing sensory changes in pediatric oncology patients, with initial recruitment challenges leading to protocol amendments.
The ROBIN trial will investigate the molecular effects of standard short course radiotherapy on rectal cancer and its impact on the immune system.
A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.
SillaJen is conducting Phase 1 trial of BAL0891, evaluating its safety and tolerability in advanced solid tumors and relapsed/refractory AML.
The NORM-HF study aims to show that the FIRE1 NORM™ System is superior to standard care in managing heart failure.
A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.
A study is underway to evaluate nemtabrutinib against ibrutinib or acalabrutinib in treatment-naive CLL/SLL patients.
A Phase 2/3 study is evaluating zilovertamab vedotin in combination with standard care for rrDLBCL, with a protocol amendment discontinuing enrollment in one cohort.
A phase I/II trial (ScarASC) is underway to evaluate the efficacy of allogeneic adipose-derived stem cells for treating hypertrophic scars in burn survivors.
A randomized trial is assessing whether S-ICD implantation without defibrillation testing is non-inferior to the standard method.
A clinical trial is assessing the safety and feasibility of R-MVST cells for patients with refractory viral infections caused by EBV, CMV, ADV, or BK virus.
STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.
The OTAC trial is assessing the safety and efficacy of hIVIG versus placebo in outpatients with COVID-19.
A clinical trial is evaluating the effectiveness of posterosuperior bundle pacing in reducing atrial fibrillation incidence in patients with sinus node dysfunction.
Signal Score
8.2
Boomerang Medical is conducting a pivotal trial to evaluate a device aimed at reducing bowel urgency in ulcerative colitis patients.
A randomized, open-label trial is underway to evaluate TQB2868 injection and anlotinib hydrochloride in combination with chemotherapy versus placebo.
A clinical trial is underway to evaluate DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, HR+ metastatic breast cancer.
A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.
A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.
AUR103 calcium is being evaluated in Phase 2 study for efficacy and safety in advanced neuroendocrine tumors.
The trial aims to establish the pharmacokinetic equivalence, safety, and immunogenicity of KSHB002 compared to ORENCIA in healthy subjects.
A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.
Polyploid giant cancer cells (PGCCs) contribute to therapy resistance and poor prognosis in ovarian cancer.
A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.
Gut bacteria metabolize Flutamide into inactive forms, reducing its therapeutic efficacy against prostate cancer.
The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.
Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.
The study demonstrates that the HPV16 E7 mRNA/LNP vaccine induces strong immune responses and tumor regression in early-stage HPV tumors in mice.
A randomized controlled trial is evaluating the impact of socio-aesthetics well-being care on quality of life, pain, and anxiety in cancer patients.
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) aims to validate biomarkers and improve clinical trial design for Alzheimer's disease.
The ALCHEMIST trial is evaluating the efficacy of adding pembrolizumab to standard chemotherapy in resected non-small cell lung cancer.
A Phase 3 trial is underway comparing GammaTile implantation with standard care in patients undergoing GBM excision.
A Phase 3 study is evaluating the safety and efficacy of L606 in patients with pulmonary hypertension due to interstitial lung disease.
A phase III trial is investigating whether 6 months of HER2-targeted therapy is more effective than 12 months for HER2-positive breast cancer patients who achieved a pathologic complete response after neoadjuvant chemotherapy.
A phase 3 trial is evaluating the efficacy and safety of orelabrutinib, CNS-penetrable BTK inhibitor, in patients with non-active Secondary Progressive MS.
A phase III trial is testing the efficacy of adding Herceptin Hylecta or Phesgo to standard chemotherapy in HER2 positive endometrial cancer.
A phase III trial is underway to evaluate the efficacy and safety of MEDI5752 in combination with standard chemotherapy in patients with unresectable pleural mesothelioma.
A Phase III trial is underway to evaluate giredestrant against standard endocrine therapy in ER-positive, HER2-negative early breast cancer.
A Phase III trial is underway to evaluate the combination of durvalumab and domvanalimab in patients with unresectable NSCLC.
A phase III trial is testing the addition of cemiplimab to standard surgery for resectable stage III/IV squamous cell skin cancer.
A phase III trial has been initiated to evaluate Hemay005 for the treatment of moderately to severely active ulcerative colitis in Chinese patients.
A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.
Signal Score
8.4
A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough.
ACADIA Pharmaceuticals is launching a master protocol for three independent studies evaluating ACP-204 in Alzheimer's Disease Psychosis.
A Phase III study is underway to evaluate SYHA1813 against investigator's choice treatment in high-grade meningioma patients.
A phase III trial is evaluating the efficacy of dinutuximab combined with standard chemotherapy and surgery for high-risk neuroblastoma in children.
A clinical trial is assessing the efficacy of adding pelvic radiotherapy to androgen deprivation therapy in patients with node-positive prostate cancer post-prostatectomy.
The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.
The Phase III METEOROID study demonstrated that ENSPRYNG (satralizumab) reduced the risk of relapses by 68% in MOGAD patients.
Company
Roche
Asset
fenebrutinib
Indication
Oncology / Diagnostics and Multiple Sclerosis / BTK Inhibitor
Status
Under Review
Signal Score
8.4
Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.
mRNA-1083 demonstrated durable antibody responses against influenza and SARS-CoV-2 for 6 months with a favorable safety profile.
A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.
A phase III trial is assessing the efficacy of adding triapine to standard cisplatin and radiation therapy for advanced-stage cervical and vaginal cancers.
The study evaluates calderasib combined with pembrolizumab as a first-line treatment for KRAS G12C mutant NSCLC.
A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.
The ADAPT-TN-IV trial will explore the efficacy of Sacituzumab Govitecan combined with Pembrolizumab in neoadjuvant therapy for TNBC.
New real-world data confirm Vabysmo's effectiveness in drying the retina for nAMD and DME, while Susvimo shows potential for sustained disease control.
The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.
A Phase 2/3 study is evaluating CMP-001 in combination with nivolumab against nivolumab monotherapy in advanced melanoma.
A Phase III trial demonstrated that Ashwagen® significantly reduced anxiety and stress markers in patients with hypertension.
Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.
In clinical trials, Foundayo demonstrated significant weight loss in women across all stages of menopause, with losses up to 30.4 lbs.
Signal Score
8.2
Roche will present new data from the Phase II studies of enicepatide and petrelintide in obesity at the ADA Scientific Sessions.
The mRNA-1283 vaccine met non-inferiority criteria against mRNA-1273 and elicited higher neutralizing antibody responses.
Signal Score
8.4
Five-year follow-up data from KEYNOTE-942 show the potential of intismeran autogene in combination with KEYTRUDA for high-risk melanoma. Additionally, KEYNOTE-522 results indicate a continued survival benefit for high-risk early-stage TNBC patients.
Signal Score
8.4
Foundayo (orforglipron) demonstrated a 57.1% greater reduction in A1C and significant weight loss compared to oral semaglutide in pivotal trials.
Intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death in high-risk melanoma patients.
Phase 3 LIBRETTO-432 results indicate an 83% reduction in the risk of disease recurrence or death with Retevmo as adjuvant therapy.
Signal Score
8.4
Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.
Foundayo (orforglipron) demonstrated up to 13% body weight reduction in adults aged 65 and older with obesity.
Signal Score
8.4
The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.
In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs (28.3%) over 80 weeks.
Signal Score
8.4
Gilead and Merck announced positive topline results from two Phase 3 studies for Islatravir/Lenacapavir, a novel oral HIV treatment.
The Phase III VOLGA trial demonstrated that perioperative Imfinzi plus neoadjuvant EV significantly improves event-free survival and shows a favorable trend in overall survival for muscle-invasive bladder cancer.
Signal Score
8.4
Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.
The TroFuse-005 trial demonstrated that sacituzumab tirumotecan significantly improved overall survival and progression-free survival compared to chemotherapy in patients with advanced or recurrent endometrial cancer.
Tozorakimab met its primary endpoint in the Phase III MIRANDA trial, showing significant reduction in COPD exacerbations.
Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.
The Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy and KEYTRUDA has been discontinued due to lack of statistically significant efficacy.
Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.
Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.
The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.
The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.
The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.
Non-coding RNAs play significant roles in regulating aerobic glycolysis in pancreatic ductal adenocarcinoma.
A novel CD2-targeted bispecific antibody combined with CD3 T cell engager shows improved efficacy and reduced toxicity in solid tumors.
A Phase 3 trial is underway to assess maridebart cafraglutide's efficacy and safety in OSA patients not using PAP therapy.
A Phase 3 maintenance study is underway to evaluate duvakitug's efficacy and safety in patients with moderately to severely active Ulcerative Colitis.
A Phase III trial is underway to evaluate TR115, an EZH2 inhibitor, against standard treatments in relapsed/refractory peripheral T/NK-cell lymphoma.
Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax regimen in previously treated CLL/SLL patients.
Lilly's AJ1-11095, a type II JAK2 inhibitor, shows an encouraging safety profile and promising clinical activity in myelofibrosis patients.
The Phase 1/2 trial demonstrated that GSK's AS03-adjuvanted H5N8 vaccine met FDA immunogenicity criteria, with higher immune responses in younger adults.
A clinical trial is proposed to evaluate the use of rivaroxaban for stroke prevention in hypertrophic cardiomyopathy patients with abnormal left atrial strain.
A new clinical trial is set up to create a biobank of human body material and clinical data from melanoma and non-melanoma patients.
A prospective randomized controlled study aims to assess the effectiveness of ultrasound-guided central venous catheterization in reducing complications among obese ICU patients.
COVAC-2, a recombinant protein vaccine, demonstrated a favorable safety profile and strong immune responses as a booster in previously vaccinated adults.
A Phase II clinical trial is underway to evaluate the efficacy and safety of SAL0140 at varying doses in patients with primary aldosteronism.
A clinical trial is underway to determine the maximum tolerated dose of MRI-guided SBRT for liver metastases.
Signal Score
8.4
A Phase 3 clinical study is underway to assess CU-20101's efficacy and safety against Botox for glabellar lines.
A clinical trial is underway to compare MRI-guided IMRT dosing against standard IMRT in HPV positive oropharyngeal cancer patients.
A randomized trial is underway to evaluate surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors.
A first-in-human phase I/IIa trial is evaluating the safety and efficacy of [212Pb]VMT01, an alpha-particle therapy, in combination with nivolumab for advanced melanoma.
A randomized controlled trial is evaluating the effectiveness of silicone barrier spray versus zinc oxide ointment for mild incontinence-associated dermatitis.
A clinical trial is underway to compare the effectiveness of dapagliflozin and metformin in managing weight gain from antipsychotic medications.
A clinical trial is assessing the safety and efficacy of PRS CK STORM in patients with cytokine storms from respiratory infections.
A phase 3b study demonstrated that co-administration of 4CMenB and MenACWY-CRM in adolescents is safe and immunogenic.
A clinical trial is evaluating the effects of preoperative versus intraoperative midazolam on stress and recovery in children undergoing adenotonsillectomy.
A clinical trial is underway to evaluate the efficacy of CXD combined with a restrictive ketogenic diet in treating MASLD.
This clinical trial aims to adapt and evaluate Behavioral Activation for veterans with co-occurring AUD and PTSD against Relapse Prevention.
A pilot trial is evaluating a digitally enhanced stepped-care approach for treating depression in primary care settings.
A registry study is collecting data on minimally invasive cancer treatments using spectral angio-CT guidance in the Netherlands and France.
The AIM-MET study is evaluating a microbiome-targeted nutritional product's effect on glycemic control in type 2 diabetes over 24 weeks.
A Phase 3 clinical trial is underway to evaluate the efficacy and safety of pridopidine in treating amyotrophic lateral sclerosis (ALS).
Low-intensity pulsed ultrasound combined with microbubbles significantly increased BBB permeability, enhancing amphotericin B delivery and efficacy against cryptococcal meningitis in a murine model.
A randomized trial will compare the effectiveness of Prolonged Exposure therapy, paroxetine, venlafaxine, and their combination in veterans with PTSD.
A Phase II trial is underway to evaluate the efficacy of venetoclax combined with rituximab in older patients with untreated mantle cell lymphoma.
Signal Score
8.4
In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs and significant reductions in knee osteoarthritis pain.
This clinical trial aims to compare the analgesic efficacy of Serratus Posterior Superior Intercostal Plane Block and Thoracic Paravertebral Block in reducing postoperative opioid consumption after open thoracotomy.
A randomized pilot study is underway to evaluate the safety and efficacy of geniculate artery embolization in knee osteoarthritis.
The EMERALD-3 Phase III trial demonstrated a statistically significant improvement in progression-free survival for Imfinzi plus Imjudo in patients with unresectable liver cancer.
Efzimfotase alfa demonstrated significant improvement in bone health in treatment-naïve pediatric patients and maintained safety in those previously treated with Strensiq.
This clinical trial will evaluate the impact of avoiding pulmonary artery catheters on recovery outcomes in cardiac surgery patients.
The TAPUR study aims to assess the effectiveness of FDA-approved drugs targeting specific genomic variants in advanced cancer patients.
Tozorakimab met primary endpoints in both OBERON and TITANIA Phase III trials, showing significant reductions in COPD exacerbations.
A clinical trial is underway to compare the efficacy of Zhuochuming® using a 3+T&E regimen against a 3+PRN regimen in treating treatment-naïve patients with diabetic macular edema.
A clinical trial is investigating the feasibility of neuromuscular electrical stimulation (NMES) to improve recovery in older adults with AECOPD and community-acquired pneumonia.